

## NantKwest Announces Pricing of Initial Public Offering

July 28, 2015 1:58 AM ET

CULVER CITY, Calif.--([BUSINESS WIRE](#))--NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the pricing of its initial public offering of 8,288,000 shares of its common stock at a price to the public of \$25.00 per share. All of the shares are being offered by NantKwest. The shares are expected to begin trading on The Nasdaq Global Select Market on July 28, 2015, under the symbol "NK." In addition, NantKwest has granted the underwriters a 30-day option to purchase up to an additional 1,243,200 shares of its common stock. Concurrently with the initial public offering, NantKwest is also selling 680,000 shares of its common stock in a separate private placement to Celgene Corporation, an existing stockholder, at the initial public offering price of \$25.00 per share.

BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC and Piper Jaffray are acting as joint book-running managers for the offering, and MLV & Co. LLC is acting as co-manager.

Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on July 27, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department, or by email at [dg.prospectus\\_requests@baml.com](mailto:dg.prospectus_requests@baml.com); Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [prospectus@citi.com](mailto:prospectus@citi.com), or by telephone at (800) 831-9146; Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by email at [Prospectus\\_Department@Jefferies.com](mailto:Prospectus_Department@Jefferies.com); or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by email at [prospectus@pjc.com](mailto:prospectus@pjc.com), or by telephone at (800) 747-3924.

### Contacts

NantKwest

Jen Hodson, 562-397-3639

[jen@nantworks.com](mailto:jen@nantworks.com)